文献速递浆细胞疾病

意大利一家血液学三级诊疗中心复发难治性多发性骨髓瘤患者治疗模式与结局的真实世界评估

Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre.
PubMed 文献 · Br J Haematol · 2023-01-17

该研究分析2011至2021年治疗的413例多发性骨髓瘤患者的治疗路径、脱落率和难治模式。LOT-2至LOT-5的脱落率分别为26%、27%、34%和37.5%,后续LOT为50%;中位PFS从LOT-1的40.5个月降至LOT-5的4.7个月。来那度胺难治比例在早期和近期队列中升高。

要点

  • LOT-2至LOT-5脱落率分别为26%、27%、34%和37.5%,后续LOT为50%。
  • 中位PFS从LOT-1至LOT-5分别为40.5、19.5、10.3、6和4.7个月。
  • LOT-1后复发患者中来那度胺难治比例:2019年前开始治疗者26% vs 2021年及以后开始治疗者64.5%。

核心结论

  • 本分析中达到后续LOT的患者比例高于既往报告,早期难治性增加需要更快更有效的治疗许可流程。

研究设计与样本

  • 研究分析了2011年至2021年治疗的413例多发性骨髓瘤患者的治疗路径、脱落率和难治模式。

主要发现

  • LOT-2至LOT-5的脱落率分别为26%、27%、34%和37.5%,后续LOT为50%。
  • 单因素分析中年龄超过65岁、ISS II/III期、超过两种合并症、未接受移植和未接受维持治疗与脱落率显著相关,但回归分析仅选择年龄超过65岁和超过2种合并症。
  • 中位PFS从LOT-1至LOT-5分别为40.5、19.5、10.3、6和4.7个月。
  • LOT-1后复发患者中来那度胺难治比例:2019年前开始治疗者26% vs 2021年及以后开始治疗者64.5%。
  • 两个队列中LOT-2后复发患者来那度胺难治比例分别为57.5%和85.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite significant improvements in therapeutic options, multiple myeloma (MM) patients experience a series of remissions and relapses requiring further lines of therapy (LOTs). We analysed treatment pathways, attrition rates (ARs) and refractoriness patterns across LOTs in 413 MM patients treated from 2011 and 2021. Across LOT-2 to LOT-5 ARs were 26%, 27%, 34% and 37.5%, being 50% for subsequent LOTs. In univariate analysis age over 65 years, international staging system (ISS) II/III, more than two comorbidities, no transplant and no maintenance therapy were significantly associated with AR but regression analysis selected only age over 65 years and more than 2 comorbidities. Median progression-free survival (PFS) was 40.5, 19.5, 10.3, 6 and 4.7 months from LOT-1 to LOT-5. Lenalidomide-refractory patients, among those relapsed after LOT-1, were 26% and 64.5% respectively, in patients starting therapy before 2019 versus in or after 2021. In the two cohorts, 57.5% and 85.5% of patients relapsed after LOT-2 were lenalidomide-refractory. Among patients not relapsed from LOT-1, 80% are receiving continuous lenalidomide and could become lenalidomide-refractory, whereas 91% and 51.5% of patients in LOT-2 could become potential lenalidomide- and daratumumab-refractory respectively. In our analysis the rate of patients reaching subsequent LOTs was higher than previously reported and the increase in early refractoriness would require faster and more efficient treatment licensing processes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Morè S, Corvatta L, Manieri MV, et al. Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre. Br J Haematol. 2023. PMID: 36648095. doi:10.1111/bjh.18658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。